Wee Joo Chng

Promiscuous Mutations Activate the Noncanonical NF-κB Pathway in Multiple Myeloma

Jonathan J. Keats, Rafaël Fonseca, Marta Chesi et al. · Cancer Cell · 2007 · 980 citations · Full text

Hematological Malignancy, Medicine, Cancer Cell Biology +7

Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group

Pieter Sonneveld, Hervé Avet‐Loiseau, Sagar Lonial et al. · Blood · 2016 · 907 citations · Full text

Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study

Meletios Α. Dimopoulos, Philippe Moreau, Antonio Palumbo et al. · The Lancet Oncology · 2015 · 834 citations · Full text

Hematological Malignancy, Oncology, Dexamethasone Versus Bortezomib +8

A common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer

King Pan Ng, Axel M. Hillmer, Charles Chuah et al. · Nature Medicine · 2012 · 550 citations

Intrinsic Resistance, Tumor Biology, Radiation Oncology +11

Gene expression profiling and correlation with outcome in clinical trials of the proteasome inhibitor bortezomib

George Mulligan, Constantine S. Mitsiades, Barbara M. Bryant et al. · Blood · 2006 · 409 citations · Full text